Navigation Links
UCLA researchers develop new way to screen for brain cancer stem cell killers
Date:10/11/2011

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

Glioblastoma is one of the deadliest malignancies, typically killing patients within 12 to 18 months. These brain cancers consist of two kinds of cells, a larger, heterogeneous population of tumor cells and a smaller sub-population of stem cells, which are treatment-resistant.

The screening system was specifically designed to find drugs that can target that sub-population and prevent it from re-seeding the brain cancer, said study senior author Dr. Harley Kornblum, a Jonsson Cancer Center scientist and a professor of psychiatry and biobehavioral sciences.

"We're pleased that we can present a different way to approach the discovery of potential new cancer drugs," said Kornblum, who also is a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. "And by finding these drugs, we may be able to reveal things about the biology of these cancer stem cells."

The study appears in the Oct. 10 issue of Molecular Cancer Therapeutics, a peer-reviewed journal of the American Association of Cancer Research.

After testing more than 31,000 compounds from seven chemical libraries in an initial screen, the team came up with 694 that showed some activity against the brain cancer stem cells. After further narrowing the field down to 168 compounds, they decided to focus on four in future studies because they most successfully inhibited the brain cancer stem cells, Kornblum said.

What Kornblum and his team did in their approach was sort of a reverse of the usual screening processes. Typically, researchers doing high-throughput screening are seeking a drug to hit a specific target they know is on a cancer cell, perhaps a protein that is causing it to grow or a gene that keeps it from dying. In this case, Kornblum said, the team was basically shooting in the dark because the biology of these brain cancer stem cells is largely unknown.

"When brain cancer stem cells were first discovered, we all realized rapidly that we would need to find drugs that attack these cells specifically, because they're resistant to our conventional therapies," Kornblum said. "We needed a way to kill these stem cells."

UCLA's high-throughput screening technology is capable of screening as many as 100,000 compounds in a single day. Researchers generally develop cancer cells lines and then create an assay, a procedure in molecular biology to test or measure the activity of a drug or biochemical compound in an organic sample, in this case the cancer cells.

The cells are loaded into plates with 384 wells each and the drugs are added. The plates are about the size of the palm of an adult hand. The computerized, robotic screening system executes the process from start to finish, adding the compounds sitting in the tiny wells in the plates to the cancer cells, located in corresponding assay plates.

In this study, Kornblum and his team had a few clues to help them in narrowing down potential candidates that kill brain cancer stem cells. One method they used was based on a prior discovery by Jonsson Cancer Center researchers. The researchers had identified genes that correlate with how aggressive a brain tumor is, so Kornblum decided to try to find potential drug candidates that might reduce the expression of these genes. Another approach was to figure out which of the molecules killed brain cancer stem cells with a greater potency than they attacked other cells within glioblastoma.

To grow his cell lines, Kornblum used human tissue taken from UCLA patients diagnosed with glioblastoma. He knew that a certain method of culturing brain cancer cells resulted in a large number of brain cancer stem cells in the population. These cells were then screened with a molecular library of 31,624 compounds available through the cancer center's Molecular Screening Shared Resource. These compounds encompass a wide range of structures and therefore have the possibility of influencing virtually all cellular functions.

"We decided on this type of approach because, although we have learned a great deal about brain cancer stem cells in the past several years, we still have not discovered enough of their biology to be sure that any single target will be the right one to hit," Kornblum said.

Going forward, Kornblum and his team will further study the four identified "lead" compounds to see if they help reveal the biology of the brain cancer stem cells and potentially result in a new and more effective therapy for these deadly brain cancers.

"One of our goals was to determine whether some compounds selectively act on glioblastoma stem cells compared to the less tumorigenic cells from the same tumor," the study states. "This selectivity may allow for the delineation of pathways and processes that are highly important to these cells. By making sure that a drug candidate has the potential to attack these stem cells, one might ensure the highest chance of therapeutic success."


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Researchers find race disparity in post-hospital arrival homicide deaths at trauma centers
2. Researchers Assess What Works Best to Prevent PTSD
3. Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients
4. Researchers question key quality measure for asthma
5. Researchers from Boston University receive grant to develop improved virus detection system
6. Researchers review studies on CCSVI-MS link
7. Researchers call for more awareness of male breast cancer as cases rise
8. Researchers transform iPhone into high-quality medical imaging device
9. Fox Chase researchers identifiy more accurate treatment delivery for robotic radiosurgery system
10. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
11. Childrens National researchers make breakthrough in understanding white matter development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for ... consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as ... of all charities reviewed by Charity Navigator and earns ANRF a spot on their ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America ... secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves ... Bowman brings an intimacy with the issues and challenges veterans face with the VA. ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
(Date:6/23/2017)... ... 2017 , ... Ensuring meat products have reached the proper ... of correctly using a meat thermometer. The videos feature University of California Davis ... food safety habits. Dr. Bruhn explains the variety of meat thermometers available on ...
(Date:6/23/2017)... ... 23, 2017 , ... MD Now Urgent Care opened its newest ... overall and marks the urgent care center's eighth location in Miami-Dade county. , The ... shopping mall. The new clinic offers a wide array of services to ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology: